Sprawdź aktualne oferty i ubiegaj się o pracę w spółkach Grupy Novartis na całym świecie. Business Data Analyst II Regular, Full time India Hyderabad (Office) Wrz 11, 2024 ...
Manager- Digital Analytics Regular, Full time CTS India Hyderabad (Office) Set 11, 2024 Analyst - Digital Analytics Regular, Full time CTS India Hyderabad (Office) Set 11, 2024 SSO Study Start-Up Team ...
Senior Principal Product Operations Manager Regular, Full time Innovative Medicines Indien Hyderabad (Office) Sep 11, 2024 Manager- Digital Analytics Regular, Full time CTS Indien Hyderabad (Office) ...
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...
诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件 ...
Health Economics and Outcomes Research Manager Regular, Full time Innovative Medicines United Kingdom London (The Westworks) set 18, 2024 ...
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1,2 Kisqali ® ...
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback